POST Online Media Lite Edition


Mylan: Teva's stake buy violates U.S. anti-trust rules

Staff writer |
Mylan said Teva Pharmaceutical Industries, which has made an unsolicited offer for the company, violated U.S. anti-trust rules by acquiring a stake.

Article continues below

"We consider Teva's stakebuilding as a further indication of its intention to meddle with our business, strategy and mission while remaining unclear as to its actual intentions," Mylan said in a letter addressed to Teva's chief executive, Erez Vigodman.

Teva disclosed a 1.35 percent stake in Mylan last week. Mylan did not clarify which anti-trust rule Teva violated.

Mylan said on Monday there was still no clarity whether Teva would make a formal offer, almost six weeks since Teva's offer for about $40 billion.

What to read next

Mylan wants to block Teva, Teva wants to block Mylan
Abbott to vote for Mylan's acquisition of Perrigo
Teva completes purchase of 4.61% interest in Mylan